The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.
The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.
The Chemours Company reported an insider transaction by Shane Hostetter, its Chief Financial Officer. The filing shows 3,021 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The report indicates these withholding transactions were exempt under Rule 16b-3 and that no shares were sold in connection with the withholding.
The filing lists a per-share price of $12 for the withheld shares and shows total beneficial ownership following the transaction of 57,115.1539 shares, which the filer states includes directly owned shares, restricted stock units and dividend equivalent units.
The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.
The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.
On 08/01/2025, Chemours (CC) President & CEO Denise Dignam filed a Form 4 disclosing an automatic share withholding (Transaction Code F) tied to vested restricted stock units.
- Shares withheld: 466 common shares at $11.50, executed solely to satisfy tax obligations; no open-market sale occurred and the trade is Rule 16b-3 exempt.
- Remaining ownership: 187,478.1549 shares held directly, meaning the transaction reduced her stake by roughly 0.25%.
- Insider role: Dignam serves as both President & CEO and Director, maintaining substantial equity alignment with investors.
The event is routine, immaterial to Chemours’ capital structure and does not signal a change in insider sentiment.
Chemours Company (CC) Form 4 filing – 8/1/2025
President, Thermal & Specialized Solutions, Joseph T. Martinko reported an automatic share disposition coded “F,” indicating 649 common shares were withheld by the company at $11.50 to cover taxes triggered by the vesting of restricted stock units (RSUs) and related dividend-equivalent units. No shares were sold on the open market; therefore, the transaction is exempt under Rule 16b-3.
- Post-transaction beneficial ownership: 30,936.6241 shares (direct)
- Insider role: Executive officer – President, Thermal & Specialized Solutions
- Purpose: Tax withholding; routine administrative event
Given the small share count (<0.1% of total ownership) and non-cash nature, the filing is considered operationally routine with minimal investment impact.
Chemours (CC) posted a sharp swing to loss in Q2-25. Net sales rose 3.9% YoY to $1.615 billion, but gross profit contracted 9.7% to $278 million and SG&A ballooned to $437 million (vs. $154 million), driving a GAAP net loss of $380 million (-$2.54 per diluted share) versus $60 million profit a year ago. Six-month sales improved 2.3% to $2.983 billion, yet the company recorded a H1-25 loss of $384 million (-$2.56 per share) against $113 million income in H1-24.
Cash from operations was a modest -$19 million, far better than the -$910 million outflow reported in the prior-year period, helped by smaller working-capital drains. Free cash flow remained negative as Chemours spent $127 million on capex. Cash and equivalents fell to $502 million from $713 million at year-end, while long-term debt inched up to $4.102 billion. Total equity shrank to $239 million, reflecting the loss and a dividend cut to $0.0875 per share (vs. $0.25 last year).
The company cites $954 million unused capacity on its revolving credit facility and believes liquidity is adequate through August 2026, but warns that adverse outcomes in PFAS and other legal/environmental matters could be material. Management revised prior-period financials for presentation errors; impacts were immaterial.